Since inception, Tetraphase has been using its proprietary chemistry technology to build a pipeline of antibiotic candidates to address the serious and growing unmet medical need in the treatment of multidrug-resistant bacterial infections.
We are developing our lead product candidate, eravacycline, as a broad-spectrum intravenous and oral antibiotic for the treatment of multidrug-resistant (MDR) infections, including those caused by MDR Gram-negative bacteria. We developed eravacycline using our proprietary chemistry technology. Eravacycline is a novel, fully synthetic tetracycline antibiotic in a phase 3 program called IGNITE (Investigating Gram-negative Infections Treated with Eravacycline) for the treatment of complicated intra-abdominal infections (cIAI)(IGNITE1) and complicated urinary tract infections (cUTI)(IGNITE2).
TP-271, a novel antibiotic currently in preclinical development, is being developed to combat respiratory disease caused by bacterial biothreats and antibiotic-resistant public health pathogens. As development continues, TP-271 is anticipated to protect against certain biothreats agents, including Francisella tularensis, which causes tularemia; Yersinia pestis, which causes bubonic plague; Bacillus anthracis, which causes anthrax disease; and bacterial pathogens associated with community-acquired bacterial pneumonia (CABP).
We are developing TP-271 with the financial assistance of the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID), which awarded us a $36 million contract in October 2011 to support TP-271's development, manufacturing, and clinical activities, from which we may receive up to approximately $13 million in funding.
TP-6076 (2nd Generation Gram-negative Program)
We are using our proprietary chemistry technology to pursue the discovery and development of additional tetracycline-derived compounds effective against the most urgent multidrug-resistant Gram-negative bacterial health threats identified by the CDC in a September 2013 report. Pathogens targeted include carbapenem-resistant variants of Klebsiella pneumoniae, Acinetobacter baumanni, Escherichia coli and Pseudomonas aeruginosa. We have generated compounds that have demonstrated potent activity against a broad range of these multidrug-resistant Gram-negative pathogens. We have identified TP-6076 as a lead preclinical candidate from these compounds and are currently evaluating it in IND-enabling studies.